Premium
Molecular characterization of paediatric idiopathic hypereosinophilia
Author(s) -
Rapanotti Maria Cristina,
Caruso Roberta,
Ammatuna Emanuele,
Zaza Serena,
Trotta Laura,
Divona Mariadomenica,
Cicconi Laura,
Funaro Daria,
Federici Giorgio,
Amadori Sergio,
De Rossi Giulio,
LoCoco Francesco
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08394.x
Subject(s) - hypereosinophilia , gene rearrangement , fusion gene , immunology , hematology , lymphoma , breakpoint cluster region , imatinib , hypereosinophilic syndrome , medicine , pdgfra , bone marrow , imatinib mesylate , cancer research , biology , eosinophilia , genetics , gene , stromal cell , receptor , myeloid leukemia , gist
Summary The hypereosinophilic syndromes (HES) include a group of heterogeneous diseases characterized by the persistent increase of the number of eosinophils in blood and bone marrow. Few cases of paediatric hypereosinophilia (pHES) have been described in the literature. Early identification of pHES that may evolve towards a lymphomyeloproliferative disease is relevant in light of prognostic and therapeutic implications. Molecular features of 10 pHES patients were analysed at presentation and during their clinical course, including analysis of BCR‐ABL1 and FIP1L1/PDGFRA fusion genes, quantitation of WT1 gene copy number and clonality of T‐cell receptor (TCR) and immunoglobulin heavy chain ( IGH ). All patients had normal karyotype and germline TCR configuration. Five children showed IGH clonality at presentation: of these, two developed a B non‐Hodgkin lymphoma and a B‐lineage acute lymphocytic leukaemia at six and 12 months respectively, two spontaneously reverted to a polyclonal IGH profile during the follow‐up, and the last one persisted with pHES without B‐clonal evolution after 19 months. One patient had a PDGFRA/FIP1L1 fusion and achieved hematologic and molecular remission after imatinib therapy. IGH rearrangement was observed to be a frequent molecular feature of pHES and may precede B‐cell clonal expansion and evolution into B‐cell malignancies in children.